Abstract

We studied the scientific literature and disease guidelines in order to summarize the clinical utility of genetic testing for Stargardt macular dystrophy (STGD). STGD is mostly inherited in an autosomal recessive manner and rarely in an autosomal dominant manner, with an overall prevalence of 1-5 per 10 000 live births. It is caused by variations in the ABCA4, CNGB3, ELOVL4, PRPH2 and PROM1 genes. Clinical diagnosis is based on ophthalmological examination, fluorescein angiography, electroretinography, visual field testing, optical coherence tomography and color testing. The genetic test is useful for confirming diagnosis, and for differential diagnosis, couple risk assessment and access to clinical trials.

Details

Title
Genetic testing for Stargardt macular dystrophy
Author
Abeshi, Andi 1 ; Zulian, Alessandra 2 ; Beccari, Tommaso 3 ; Dundar, Munis 4 ; Fabiana D’Esposito 5 ; Bertelli, Matteo 6 

 MAGI Balkans, Tirana, Albania; MAGI’S Lab, Rovereto, Italy 
 MAGI Euregio, Bolzano, Italy 
 Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy 
 Department of Medical Genetics, Erciyes University Medical School, Kayseri, Turkey 
 Head and Neck Department, School of Medicine and Surgery, University of Naples “Federico II”, Napoli, Italy; ICORG (Imperial College Ophthalmology Research Group), Western Eye Hospital, London, UK; MAGI Euregio, Bolzano, Italy 
 MAGI’S Lab, Rovereto, Italy; MAGI Euregio, Bolzano, Italy 
Pages
105-107
Publication year
2017
Publication date
2017
Publisher
De Gruyter Poland
e-ISSN
2564615X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3156966125
Copyright
© 2017. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.